ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO688

Clinical Characterization and Outcomes of Lupus Nephritis in the Colombian Caribbean: Data from the Lupus Nephritis Register (RENELUP)

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Aroca Martinez, Gustavo, Universidad Simon Bolivar Facultad de Ciencias de la Salud, Barranquilla, Atlántico, Colombia
  • Dominguez-Vargas, Alex, Universidad del Norte Division Ciencias de la Salud, Barranquilla, Atlántico, Colombia
  • Gonzalez Torres, Henry J., Universidad Simon Bolivar Facultad de Ciencias de la Salud, Barranquilla, Atlántico, Colombia
  • Musso, Carlos Guido, Universidad Simon Bolivar Facultad de Ciencias de la Salud, Barranquilla, Atlántico, Colombia
  • Sanguino, Maria Gabriela, Universidad del Norte Division Ciencias de la Salud, Barranquilla, Atlántico, Colombia
  • Velez, Maria De Los Ángeles, Universidad Simon Bolivar Facultad de Ciencias de la Salud, Barranquilla, Atlántico, Colombia
  • Gomez Escorcia, Lorena, Universidad Simon Bolivar Facultad de Ciencias de la Salud, Barranquilla, Atlántico, Colombia
  • Palma, Maria F., Universidad Simon Bolivar Facultad de Ciencias de la Salud, Barranquilla, Atlántico, Colombia
  • Roncallo, Camilo José, Clinica de la Costa Ltda, Barranquilla, Atlántico, Colombia
  • Sepulveda Ospino, Carlos Jose, Universidad Simon Bolivar Facultad de Ciencias de la Salud, Barranquilla, Atlántico, Colombia
  • Vallejo Patiño, Manuela, Universidad Simon Bolivar Facultad de Ciencias de la Salud, Barranquilla, Atlántico, Colombia
  • Orozco, Jesús Alfonso, Universidad Nacional de Colombia Facultad de Medicina, Bogota, Cundinamarca, Colombia
  • Ricardo Garcia, Hernando R., Clinica de la Costa Ltda, Barranquilla, Atlántico, Colombia
  • Barraza, Natalia, Clinica de la Costa Ltda, Barranquilla, Atlántico, Colombia
  • Martinez Bayona, Alvaro A., Universidad Simon Bolivar Facultad de Ciencias de la Salud, Barranquilla, Atlántico, Colombia
  • Puche Padilla, Jesús David, Universidad Libre - Campus Barranquilla, Barranquilla, Colombia
  • Egea Bermejo, Eduardo, Universidad del Norte Division Ciencias de la Salud, Barranquilla, Atlántico, Colombia
  • Garavito De Egea, Gloria, Universidad del Norte Division Ciencias de la Salud, Barranquilla, Atlántico, Colombia
  • Navarro Quiroz, Elkin, Universidad Simon Bolivar Facultad de Ciencias de la Salud, Barranquilla, Atlántico, Colombia
  • Espitaleta, Zilac, Universidad Simon Bolivar Facultad de Ciencias de la Salud, Barranquilla, Atlántico, Colombia
  • Cadena Bonfanti, Andres, Universidad Simon Bolivar Facultad de Ciencias de la Salud, Barranquilla, Atlántico, Colombia
  • Fontalvo, Jorge Rico, Universidad Simon Bolivar Facultad de Ciencias de la Salud, Barranquilla, Atlántico, Colombia
Background

LN is a severe manifestation of SLE, impacting outcomes directly and indirectly through therapy. LN varies across populations. Registries are crucial for understanding LN and assessing therapies. This study evaluates LN in RENELUP to assess its status in the Colombian Caribbean.

Methods

A multicenter cohort of 579 LN patients enrolled from 2008 to 2023. RENELUP, a JAVA-based web app, recorded demographic data, severity, outcomes, treatments, and mortality. Patients were grouped into Proliferative (Class III-IV) and Non-Proliferative (Class I-II-V) LN using ISN/RPS criteria. Chi-square/Mann-Whitney U tests evaluated renal survival using Kaplan-Meier estimator.

Results

Most patients were female (87%). Mean age was 41.1±13.1 years. Proliferative LN class IV was the main profile (62%). Proliferative LN had higher serum creatinine, proteinuria, activity index compared to Non-Proliferative LN (p<0.05). Hematuria, chronicity, low C3/C4, and clinical response were similar between LN classes. Overall SLEDAI-2K was 15.4±2.5. MMF (64%) was used as main induction therapy. Renal survival comparable based on serum creatinine at first presentation (p>0.05).

Conclusion

Our study provides insights into LN in the Colombian Caribbean. Predominant proliferative LN Class IV with significant renal involvement was observed. Moderate disease activity and MMF as main induction therapy highlight clinical management in this population, emphasizing the importance of patient registries for monitoring disease and treatment outcomes.